MedTrace Logo

Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer

NCT02238366 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 368

Last updated 2019-07-25

No results posted yet for this study

Summary

The purpose of this study is to collect some parameters which may help to provide guidance on how Androgen Deprivation Therapy (ADT) drugs are renewed and physician satisfaction.

Conditions

Interventions

DRUG

triptorelin

This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2019-06-06
Completion
2019-06-06

Countries

  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238366 on ClinicalTrials.gov